Health Care Dominates Week’s U.S. IPOs

As a practicing dentist I personally like and use BioHorizons dental implants (among other brands) but I would not buy shares in the company.

There are many dental implant manufacturers and each make claims for the superiority of their brand (e.g. Laser-Lok).  Beyond a certain point in quality many implant dentists feel that “a screw is a screw” and success depends more on how the implant is placed surgically and the quality of the prosthesis it supports.  In other words, success depends upon the carpenter not the screw.

Competition is fierce and discounting is commonplace in BioHorizons core business of dental implants and it became more intense in November 2010 with the purchase of Implant Direct by Sybron, a division of Danaher.  I can understand why the private equity firm behind BioHorizons wants to recoup their investment now but they can keep their stock.

Read The Wall Street Journal article.

Categorised in: Dr. Dorfman on WSJ.com

This post was written by Dr. Jeffrey Dorfman